Quick verdict
The “Stamets Stack” combines a mushroom, Hericium erinaceus or Lion’s Mane, a psychedelic, psilocybin, and nicotinic acid, or niacin. The claimed synergy has never been demonstrated in a randomized clinical trial. The arguments about NGF, BDNF and vasodilation piece together data from different models, doses and populations. The guide to natural and synthetic nootropics places these three ingredients within categories with different evidence bases and statuses.
Controlled microdosing trials do not confirm reliable improvements in creativity or cognition. The small Lion’s Mane trials do not justify promises of neuronal regeneration. A niacin flush is not proof of transport to nerves.
In France, psilocybin and psilocin are classified as narcotics. I therefore provide no doses, schedules, cultivation instructions or sourcing information. This analysis addresses evidence and safety, not how to carry out prohibited use.
Where does the promise come from?
The protocol was proposed by Paul Stamets, a mycologist and entrepreneur in the mushroom industry. His reasoning can be summarized as follows: psilocybin might promote plasticity linked to 5-HT2A receptors, Lion’s Mane might stimulate NGF, and niacin might improve peripheral distribution through its vasodilatory effects.
Mechanistic reasoning can justify a study. It cannot predict the outcome of the combination. Three problems remain unresolved:
- effects observed in cells or animals do not guarantee a benefit in humans
- two active substances can cancel each other out or increase adverse effects
- an increase in a plasticity marker does not mean better memory or better mental health
Neuroplasticity is not inherently good, either. The brain also reinforces fears, habits and chronic pain. The learning context and psychological support matter as much as the biological signal.
Psilocybin: do not extrapolate from high doses to microdosing
Psilocybin is converted into psilocin, which acts on serotonin receptors, particularly 5-HT2A. Supervised clinical trials are studying psychedelic doses, with preparation and support, for certain forms of depression or addiction. These results do not carry over to microdosing.
A microdose aims for low, repeated exposure, often without a pronounced psychedelic effect. It is a different intervention in intensity, frequency and context. You cannot take a high-dose therapeutic study and simply divide up its benefit.
An unconvincing double-blind trial
A 2022 study followed 34 people who were starting to microdose psilocybin mushrooms. In a double-blind, placebo-controlled design, participants completed assessments of subjective experience, creativity, cognition, perception and EEG activity.
The active dose produced more pronounced subjective effects, especially among participants who correctly identified their condition. The researchers found no evidence of improved well-being, creativity or cognition. Some changes pointed toward cognitive impairment.
The study is small and does not settle the question. Nevertheless, it is enough to challenge claims of certain gains in creativity or focus. To explore another approach to creativity, the role of the Default Mode Network in generating ideas helps explain the value and limitations of taking a break.
The role of expectations
In a self-blinding citizen science study involving 191 participants, psychological outcomes improved over four weeks in both the microdose and placebo groups. There were no between-group differences in the primary outcomes. Some acute effects could be explained by unblinding.
A rapid review of 19 controlled studies concludes that it is still too early to say all effects are placebo effects. It also highlights small samples, limited doses, nonclinical populations and difficulties with blinding. The rigorous conclusion is therefore uncertainty, not validation.
Lion’s Mane: an interesting mechanism, modest human evidence
Hericium erinaceus contains several families of compounds. Hericenones are often associated with the fruiting body and erinacines with the mycelium. Their amounts depend on the species, strain, substrate and extraction method.
Cell studies have observed stimulation of NGF synthesis or the growth of neuronal extensions. The study often cited as demonstrating an effect on NGF involved a nerve cell line, not humans taking a supplement. It does not show that the compounds cross the blood–brain barrier in useful amounts after ingestion.
A small Japanese trial in older adults with mild cognitive impairment reported an improvement in a cognitive score over 16 weeks with Lion’s Mane powder, followed by a decline after discontinuation. The sample included around 30 participants, and the product is not equivalent to every extract sold today.
Other small trials explore mood or cognition, with heterogeneous results. None demonstrates nerve regeneration, dementia prevention or synergy with psilocybin.
If you want to assess this mushroom separately, our analysis of the cognitive benefits of Lion’s Mane · FR details the products studied and the limitations.
Niacin: the flush is not a delivery system
Niacin encompasses nicotinic acid and nicotinamide, two forms of vitamin B3 with different effects. Nicotinic acid frequently causes a flush: redness, warmth, tingling and itching, linked in particular to prostaglandins and skin vasodilation.
This visible phenomenon can give the impression that the other compounds are being “pushed” toward the extremities. No clinical study shows that the flush increases the concentration of psilocin or Lion’s Mane compounds in the brain, an injured nerve or a synapse.
The blood–brain barrier is not a pipe you open by making your skin turn red. Molecules cross it according to their structure, transporters, protein binding and metabolism.
At high doses, nicotinic acid can cause hypotension, dizziness, digestive problems, increased blood glucose, hyperuricemia and liver injury, depending on the form and duration of use. Adding an adverse effect to make the protocol feel tangible is not proof of efficacy.
No evidence of “double neuroplasticity”
The formula NGF plus BDNF equals consolidated new connections is appealing as an explanation, but scientifically oversimplified. Neurotrophic factors have multiple actions that depend on the tissues, receptors and timing.
The extrapolation errors are as follows:
- 5-HT2A activation does not automatically mean a sustained increase in BDNF in humans
- increased NGF in a cell culture does not mean myelination in the human brain
- combining two mechanisms does not prove synergy
- biological plasticity does not mean useful learning
- an EEG change does not mean cognitive improvement
To validate the stack, a trial would at least need to compare placebo, each component, certain combinations and the full mixture, with blinding, a standardized product and predefined outcomes. That trial does not exist.
Legality in France
The French order of February 22, 1990 classifies psilocybin, psilocin and the hallucinogenic mushrooms concerned as narcotics. A small quantity or an intention to enhance “performance” creates no exemption.
Possession, purchase, importation, cultivation, transport and transfer therefore carry legal risks. A kit sold from another country is not proof of legality in France.
Lion’s Mane and niacin are not narcotics. That does not validate a treatment claim, just any dose or a product’s quality.
Risks of microdosing and the stack
The absence of a full psychedelic experience does not mean an absence of effects. Trials and surveys report anxiety, physiological discomfort, sleep disturbances, headaches and concentration difficulties in some people, among other effects.
Risk factors include:
- a personal or family history of psychosis or bipolar disorder
- serotonergic medication or another psychotropic drug
- heart disease or uncontrolled hypertension
- pregnancy or breastfeeding
- driving, operating machinery and safety responsibilities
- a product of uncertain identity or potency
Repeated microdosing also raises unresolved questions about the chronic cardiovascular effects of serotonergic agonists. The absence of a robust signal in small, short trials is not enough to establish safety over months or years.
Extreme agitation, suicidal thoughts, confusion, chest pain, a seizure or psychotic symptoms require urgent medical help. Be honest about the products taken. A pharmacist should also check for interactions if you take medication.
No “equivalent legal stack”
Replacing psilocybin with caffeine, L-theanine and rhodiola reproduces neither its pharmacology nor a demonstrated therapeutic effect. Stacking legal products does not create equivalent neuroplasticity and increases the number of possible interactions.
The best-established ways to support learning and preserve cognition remain less spectacular:
- sufficient sleep and treatment of any sleep disorder
- appropriate aerobic exercise and strength training
- active learning with spaced recall
- addressing sensory impairments and cardiovascular risk factors
- care for diagnosed depression, anxiety or ADHD
- reducing alcohol and substances that impair sleep
For anxiety, our guide to psilocybin microdosing · FR directly compares personal accounts with controlled trials.
Independent verdict
The Stamets Stack is a commercial and mechanistic hypothesis, not a validated clinical protocol. Each component has its own body of research, but no study shows that combining them produces a useful increase in neuroplasticity.
Controlled microdosing data are mixed and often consistent with a substantial role for expectations. Human studies on Lion’s Mane remain small. The niacin distribution hypothesis is unproven. In France, the presence of psilocybin also makes putting it into practice illegal. The verdict is therefore not “a brilliant theory to try,” but “no evidence of synergy, real risks and an illegal protocol.”
